Nothing Special   »   [go: up one dir, main page]

HUE044730T2 - Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére - Google Patents

Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére

Info

Publication number
HUE044730T2
HUE044730T2 HUE16197459A HUE044730T2 HU E044730 T2 HUE044730 T2 HU E044730T2 HU E16197459 A HUE16197459 A HU E16197459A HU E044730 T2 HUE044730 T2 HU E044730T2
Authority
HU
Hungary
Prior art keywords
antibodies
lag
combination
treat tumors
tumors
Prior art date
Application number
Other languages
English (en)
Inventor
Alan J Korman
Nils Lonberg
David J Fontana
Andres A Gutierrez
Mark J Selby
Katherine E Lewis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE044730T2 publication Critical patent/HUE044730T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16197459 2013-09-20 2014-09-18 Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére HUE044730T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361880606P 2013-09-20 2013-09-20
US201462014471P 2014-06-19 2014-06-19

Publications (1)

Publication Number Publication Date
HUE044730T2 true HUE044730T2 (hu) 2019-11-28

Family

ID=51743546

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16197459 HUE044730T2 (hu) 2013-09-20 2014-09-18 Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére
HUE18209399A HUE062317T2 (hu) 2013-09-20 2014-09-18 Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE18209399A HUE062317T2 (hu) 2013-09-20 2014-09-18 Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez

Country Status (25)

Country Link
US (4) US10081681B2 (hu)
EP (4) EP3508502B1 (hu)
JP (3) JP6595458B2 (hu)
KR (4) KR20210141789A (hu)
CN (2) CN105793287B (hu)
AU (3) AU2014323523B2 (hu)
BR (2) BR112016005816A2 (hu)
CA (1) CA2924524A1 (hu)
CY (2) CY1121723T1 (hu)
DK (2) DK3508502T5 (hu)
EA (1) EA036902B1 (hu)
ES (2) ES2728578T3 (hu)
FI (1) FI3508502T3 (hu)
HR (2) HRP20230603T1 (hu)
HU (2) HUE044730T2 (hu)
IL (3) IL290295B2 (hu)
LT (2) LT3508502T (hu)
MX (2) MX2016003103A (hu)
PL (2) PL3508502T3 (hu)
PT (2) PT3508502T (hu)
RS (2) RS64268B1 (hu)
SG (2) SG10201802264PA (hu)
SI (2) SI3508502T1 (hu)
SM (2) SMT201900332T1 (hu)
WO (1) WO2015042246A1 (hu)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
KR20210141789A (ko) 2013-09-20 2021-11-23 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
MX370449B (es) 2013-12-12 2019-12-13 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este.
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
LT3556775T (lt) * 2014-01-28 2022-01-25 Bristol-Myers Squibb Company Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102442436B1 (ko) * 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
HUE065807T2 (hu) 2014-07-17 2024-06-28 Novo Nordisk As TREM-1 ellenanyagok helyspecifikus mutagenezise viszkozitás csökkentésére
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
BR112017010110A2 (pt) 2014-11-21 2018-01-30 Bristol-Myers Squibb Company anticorpos contra cd73 e usos do mesmo
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
PT3283107T (pt) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Composições compreendendo uma combinação de ipilimumab e nivolumab
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
JP2018515474A (ja) 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
JP7048319B2 (ja) * 2015-05-12 2022-04-05 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
SMT202100131T1 (it) * 2015-07-14 2021-05-07 Bristol Myers Squibb Co Metodo di trattamento di un cancro usando un inibitore di checkpoint immunitari; anticorpo che si lega al recettore della morte programmata-1 (pd-1) o al ligando della morte programmata 1 (pd-l1)
WO2017015560A2 (en) * 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
MX2018001263A (es) * 2015-07-29 2018-04-13 Novartis Ag Nueva combinacion para el uso en el tratamiento del cancer.
MD3328419T2 (ro) 2015-07-30 2022-01-31 Macrogenics Inc Molecule de legare la PD-1 şi procedee de utilizare a acestora
US20190010231A1 (en) * 2015-08-07 2019-01-10 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
UA121914C2 (uk) * 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
EP3389714A4 (en) 2015-12-14 2019-11-13 MacroGenics, Inc. BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
CA3008244A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
RS64588B1 (sr) 2015-12-22 2023-10-31 Regeneron Pharma Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera
EP3423494A1 (en) * 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
RS61510B1 (sr) * 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3458054B1 (en) 2016-05-20 2022-02-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
CN108472349B (zh) * 2016-06-23 2022-05-24 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
AU2017290884A1 (en) * 2016-07-01 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
CN110023337B (zh) 2016-10-11 2024-01-05 艾吉纳斯公司 抗lag-3抗体及其使用方法
BR112019006876A2 (pt) 2016-10-13 2019-06-25 Symphogen As anticorpos e composições anti-lag-3
EP3541841B1 (en) 2016-11-18 2024-09-11 Les Laboratoires Servier Anti-pd-1 antibodies and compositions
CN119285772A (zh) 2016-12-07 2025-01-10 艾吉纳斯公司 抗ctla-4抗体和其使用方法
AU2018219909A1 (en) 2017-02-10 2019-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
KR20190129926A (ko) * 2017-03-15 2019-11-20 가꼬우호우징 효고 이카다이가쿠 암 면역요법의 신규 바이오마커
EP3595715A1 (en) * 2017-03-17 2020-01-22 CureVac AG Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
HRP20221254T1 (hr) 2017-04-03 2022-12-23 F. Hoffmann - La Roche Ag Imunokonjugati protutijela anti-pd-1 s mutacijskim polipeptidom interleukina-2 ili interleukina-15
KR102408873B1 (ko) 2017-04-05 2022-06-15 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
AU2018248586A1 (en) 2017-04-05 2019-09-05 Boehringer Ingelheim International Gmbh Anticancer combination therapy
US11939380B2 (en) * 2017-04-05 2024-03-26 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
AU2018253950A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-CD25 antibody-drug conjugate
JP2020517695A (ja) * 2017-04-27 2020-06-18 テサロ， インコーポレイテッド リンパ球活性化遺伝子−３（ｌａｇ−３）に対する抗体薬およびそれらの使用
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
CN108864287B (zh) * 2017-05-16 2022-08-30 上海恒润达生生物科技股份有限公司 一种靶向Mesothelin的嵌合抗原受体并对其两种修饰的方法及其用途
CN110869392A (zh) * 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
WO2018217940A2 (en) * 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
CN110720039A (zh) 2017-05-30 2020-01-21 百时美施贵宝公司 Lag-3阳性肿瘤的治疗
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
CN110691795A (zh) * 2017-05-30 2020-01-14 百时美施贵宝公司 包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
CN110719799A (zh) 2017-06-09 2020-01-21 俄勒冈州普罗维登斯健康与服务部 Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
US11390679B2 (en) 2017-08-30 2022-07-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
TW201916890A (zh) * 2017-10-17 2019-05-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
WO2019179365A1 (en) * 2018-03-20 2019-09-26 WuXi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
WO2019179422A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/lag-3 antibody molecules
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
JP2021527082A (ja) * 2018-06-11 2021-10-11 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 新規な免疫チェックポイント阻害剤
CN112672758A (zh) 2018-06-25 2021-04-16 英摩杜伦治疗学公司 癌症治疗
JP7003295B2 (ja) 2018-06-29 2022-01-20 ワイ－バイオロジクス・インコーポレイテッド Ｌａｇ－３に特異的に結合する単クローン抗体及びその用途
KR20210040080A (ko) * 2018-07-26 2021-04-12 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 lag-3 조합 요법
US20210317214A1 (en) * 2018-09-13 2021-10-14 Merck Sharp & Dohme Corp. Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL314988A (en) 2018-09-25 2024-10-01 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
RS65993B1 (sr) * 2018-10-19 2024-10-31 Bristol Myers Squibb Co Kombinovana terapija za melanom
MX2021005266A (es) * 2018-11-05 2021-06-18 Merck Sharp & Dohme Llc Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer.
KR20210089215A (ko) * 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CN113825527A (zh) * 2019-05-13 2021-12-21 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN112079925A (zh) * 2019-06-13 2020-12-15 上海健信生物医药科技有限公司 靶向lag-3的抗体和双特异性抗体及其用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
MX2022003197A (es) 2019-09-22 2022-04-11 Bristol Myers Squibb Co Perfilado espacial cuantitativo para terapia con antagonistas de la proteina del gen de activacion de linfocitos 3 (lag-3).
BR112022008191A2 (pt) 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
CN112852740A (zh) * 2019-11-27 2021-05-28 深圳市菲鹏生物治疗股份有限公司 Car-t细胞和检测方法
US20230056230A1 (en) * 2019-12-23 2023-02-23 Macrogenics, Inc. Therapy for the Treatment of Cancer
EP4095159A4 (en) 2020-01-21 2024-03-20 Shanghai Henlius Biotech, Inc. MONOCLONAL ANTI-LAG3 ANTIBODY AND METHOD FOR THE PRODUCTION THEREOF AND ITS USE
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
EP4178611A1 (en) 2020-07-07 2023-05-17 BioNTech SE Therapeutic rna for hpv-positive cancer
US20230265188A1 (en) 2020-08-28 2023-08-24 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
KR20230061430A (ko) 2020-08-31 2023-05-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 면역요법
EP4232019A1 (en) 2020-10-23 2023-08-30 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN115073588B (zh) * 2021-03-12 2024-06-18 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的安全性的方法
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
US20250042995A1 (en) * 2021-09-29 2025-02-06 Akeso Biopharma, Inc. Anti-lag3 antibody, pharmaceutical composition and use
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2024541899A (ja) 2021-10-29 2024-11-13 ブリストル－マイヤーズ スクイブ カンパニー 血液学的癌のためのｌａｇ－３アンタゴニスト療法
EP4469477A1 (en) 2022-01-26 2024-12-04 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
MX2024010310A (es) 2022-02-25 2024-08-28 Bristol Myers Squibb Co Terapia de combinacion para carcinoma colorrectal.
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
CN115845051B (zh) * 2022-12-28 2024-02-02 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗肝癌中的应用
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2024175699A1 (en) * 2023-02-23 2024-08-29 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024200571A1 (en) * 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
MX9605365A (es) 1994-05-06 1997-12-31 Roussy Inst Gustave Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.
CA2227334A1 (en) 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997032733A1 (en) 1996-03-07 1997-09-12 Eastman Chemical Company Near infrared fluorescent security thermal transfer printing and marking ribbons
EP0942973B1 (fr) 1996-11-28 2006-03-15 Institut Gustave Roussy Mutants de la proteine lag-3, leur expression et utilisation
ATE271607T1 (de) 1996-11-29 2004-08-15 Applied Research Systems Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
EA006972B1 (ru) 1998-12-23 2006-06-30 Пфайзер Инк. Моноклональное антитело человека к ctla-4 и способы его применения
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
IL147972A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Ge Pd-1, a receptor for b7-4 and uses therefor
NZ517122A (en) 1999-08-23 2004-02-27 Dana Farber Cancer Inst Inc Novel B7-4 molecules and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2002239422B2 (en) 2000-11-30 2006-12-07 E. R. Squibb & Sons, L.L.C. Transgenic transchromosomal rodents for making human antibodies
WO2002074903A2 (en) 2001-02-22 2002-09-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
ES2336433T3 (es) 2001-09-19 2010-04-13 Alexion Pharmaceuticals, Inc. Moldes modififcados mediante ingenieria genetica y su uso en amplificacion de cebador unico.
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1537878B1 (en) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
HUE035520T2 (hu) 2003-12-10 2018-05-28 Squibb & Sons Llc Interferon alfa antitestek és felhasználásuk
EP1709080B1 (en) 2004-01-09 2011-03-09 Pfizer Inc. ANTIBODIES TO MAdCAM
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
BRPI0513706A (pt) 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US7790160B2 (en) 2004-10-01 2010-09-07 Medarex, Inc. Method of treating CD30 positive lymphomas
CA2943949C (en) 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
EP1868644A1 (en) 2005-03-23 2007-12-26 Pfizer Products Incorporated Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SG163554A1 (en) 2005-07-01 2010-08-30 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
BRPI0713000A8 (pt) * 2006-06-12 2017-12-05 Trubion Pharmaceuticals Inc Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
BRPI0809674A2 (pt) 2007-03-30 2014-10-07 Medimmune Llc Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20110435A1 (es) 2008-08-25 2011-07-20 Amplimmune Inc Composiciones antagonistas del pd-1
SG172059A1 (en) 2008-12-09 2011-07-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
WO2011008092A2 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
SI2504364T1 (sl) 2009-11-24 2017-11-30 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
MX338640B (es) 2010-07-14 2016-04-25 Merck Sharp & Dohme Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos.
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
ES2692379T3 (es) * 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
CN103608040B (zh) 2011-04-20 2017-03-01 米迪缪尼有限公司 结合b7‑h1和pd‑1的抗体和其他分子
EP3378489A1 (en) * 2011-10-26 2018-09-26 Elanco Tiergesundheit AG Monoclonal antibodies and methods of use
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
ES2808654T3 (es) 2013-03-15 2021-03-01 Glaxosmithkline Ip Dev Ltd Proteínas de unión anti-LAG-3
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
KR20210141789A (ko) * 2013-09-20 2021-11-23 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
LT3556775T (lt) 2014-01-28 2022-01-25 Bristol-Myers Squibb Company Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
PT3283107T (pt) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Composições compreendendo uma combinação de ipilimumab e nivolumab
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN110691795A (zh) 2017-05-30 2020-01-14 百时美施贵宝公司 包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
CN110720039A (zh) * 2017-05-30 2020-01-21 百时美施贵宝公司 Lag-3阳性肿瘤的治疗
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
KR20210040080A (ko) 2018-07-26 2021-04-12 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 lag-3 조합 요법
RS65993B1 (sr) 2018-10-19 2024-10-31 Bristol Myers Squibb Co Kombinovana terapija za melanom
MX2022003197A (es) * 2019-09-22 2022-04-11 Bristol Myers Squibb Co Perfilado espacial cuantitativo para terapia con antagonistas de la proteina del gen de activacion de linfocitos 3 (lag-3).
BR112022008191A2 (pt) * 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
US20230265188A1 (en) * 2020-08-28 2023-08-24 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
EP4232019A1 (en) * 2020-10-23 2023-08-30 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer

Also Published As

Publication number Publication date
HRP20230603T1 (hr) 2023-09-29
SMT201900332T1 (it) 2019-07-11
IL290295B1 (en) 2024-07-01
JP7480248B2 (ja) 2024-05-09
PT3178849T (pt) 2019-06-11
ES2728578T3 (es) 2019-10-25
IL290295A (en) 2022-04-01
CY1126115T1 (el) 2023-11-15
HRP20190774T1 (hr) 2019-06-14
IL272149B (en) 2022-03-01
RS64268B1 (sr) 2023-07-31
US20210009692A1 (en) 2021-01-14
CN105793287A (zh) 2016-07-20
EA201690617A1 (ru) 2016-07-29
WO2015042246A1 (en) 2015-03-26
JP6595458B2 (ja) 2019-10-23
EP3046939A1 (en) 2016-07-27
BR122023024195A2 (pt) 2023-12-26
IL244547B (en) 2020-02-27
AU2020203056B2 (en) 2022-11-10
AU2020203056A1 (en) 2020-05-28
ES2947575T3 (es) 2023-08-11
SI3178849T1 (sl) 2019-06-28
US20200062845A1 (en) 2020-02-27
AU2014323523A1 (en) 2016-04-07
JP2023002678A (ja) 2023-01-10
SMT202300204T1 (it) 2023-09-06
MX2021002728A (es) 2021-07-16
SG10201802264PA (en) 2018-05-30
SI3508502T1 (sl) 2023-07-31
EA036902B1 (ru) 2021-01-13
FI3508502T3 (fi) 2023-06-06
AU2023200557A1 (en) 2023-03-02
PL3508502T3 (pl) 2023-07-17
DK3508502T5 (da) 2024-09-02
JP2020011984A (ja) 2020-01-23
RS58705B1 (sr) 2019-06-28
PT3508502T (pt) 2023-06-22
CN105793287B (zh) 2020-10-02
CN112516302B (zh) 2025-02-14
CN112516302A (zh) 2021-03-19
US11274152B2 (en) 2022-03-15
HUE062317T2 (hu) 2023-10-28
KR20240033088A (ko) 2024-03-12
CA2924524A1 (en) 2015-03-26
JP2016531849A (ja) 2016-10-13
US20220185892A1 (en) 2022-06-16
EP3508502B1 (en) 2023-04-26
US10081681B2 (en) 2018-09-25
KR20210141789A (ko) 2021-11-23
DK3508502T3 (da) 2023-07-31
IL272149A (en) 2020-03-31
LT3508502T (lt) 2023-07-10
MX2016003103A (es) 2016-05-26
PL3178849T3 (pl) 2019-08-30
JP7163260B2 (ja) 2022-10-31
IL290295B2 (en) 2024-11-01
SG11201601763SA (en) 2016-04-28
EP3508502A1 (en) 2019-07-10
CY1121723T1 (el) 2020-07-31
KR20160055269A (ko) 2016-05-17
LT3178849T (lt) 2019-06-10
DK3178849T3 (da) 2019-07-01
BR112016005816A2 (pt) 2017-09-19
EP4249065A3 (en) 2023-11-15
KR20230008255A (ko) 2023-01-13
EP4249065A2 (en) 2023-09-27
EP3178849B1 (en) 2019-03-20
EP3178849A1 (en) 2017-06-14
AU2014323523B2 (en) 2020-02-20
US20160222116A1 (en) 2016-08-04
IL244547A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
IL290295A (en) A combination of antibodies against lag-3 and antibodies against pd-1 for the treatment of tumors
IL237960A0 (en) Combination of anti-kir antibodies and anti-pd-1 antibodies for cancer treatment
HK1220473A1 (zh) 抗-α-突觸核蛋白抗體及使用方法
HK1206750A1 (en) Cd33 antibodies and use of same to treat cancer cd33
IL238393A0 (en) Combined treatment of her3 and anti-her2 antibodies
IL244590A0 (en) Anti-epcam antibodies and methods of use
HK1213817A1 (zh) 治療癌症的方法
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
HK1219513A1 (zh) 治療癌症的方法